menu

LEMTRADA is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS). Because of its risks, LEMTRADA is generally used in people who have tried 2 or more MS medicines that have not worked well enough. It is not known if LEMTRADA is safe and effective for use in children under 17 years of age.

View IMPORTANT SAFETY INFORMATION

Share, Send, or Save

Clinical Study Results

See results of a 2-year clinical trial of LEMTRADA vs Rebif® (interferon beta-1a) as it relates to their effect on relapsing MS. See potential risks and benefits.

STUDY 1

A 2-year clinical trial of people who had a relapse on an MS therapy

LEMTRADA: Proven to cut relapses in half over 2 years

49% fewer relapses over 2 years with LEMTRADA

The people taking LEMTRADA had nearly half as many relapses over 2 years compared to those taking Rebif.

The rate of relapses per year with LEMTRADA was 0.26 vs. 0.52 with Rebif.

LEMTRADA: Proven to help most people live relapse-free at 2 years

65% of people taking LEMTRADA were relapse-free at 2 years

65% of people taking LEMTRADA were relapse-free at 2 years compared to 47% of people given Rebif.

STUDY 2

A 2-year clinical trial of people who had never been on an MS therapy
In this study, LEMTRADA was proven to cut relapses in half (55%) vs. Rebif. The rate of relapses per year with LEMTRADA was 0.18 vs. 0.39 with Rebif.

HOW LEMTRADA WAS STUDIED

  • When LEMTRADA was being studied, researchers decided to measure LEMTRADA’s effectiveness and safety against Rebif 44 mcg, a commonly prescribed MS medication. Many other studies use a placebo, or no comparator drug at all
  • This was done in two 2-year clinical trials with a total of 1191 people with relapsing MS that were chosen at random to receive either LEMTRADA or Rebif
  • LEMTRADA was studied in both people who had a relapse on an MS therapy and in people who had never been on an MS therapy before
  • Both studies included people who had experienced at least 2 relapses during the 2 years prior to the trial, and at least 1 relapse during the year prior to the trial
  • Participants in Study 1 had to have rated 5.0 or lower on the Expanded Disability Status Scale (EDSS), while participants in Study 2 rated 3.0 or lower. EDSS measures disability progression in people with MS on a scale of 0 to 10, where 0 represents no disability
  • In addition, participants in Study 1 had to have relapsed on interferon beta or glatiramer acetate